Unbound Cloxacillin Concentrations During Continuous Infusion
Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous i
| Condition(s) | Staphylococcal Infections |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level. |
| Who can participate | Inclusion Criteria: * Age 18 years or older * Treating physician has decided to start continuous infusion of cloxacillin Exclusion Criteria: * Unwilling or unable to provide written informed consent |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Emeli Månsson |
| Locations | Västerås, Sweden |
| Start date | 2026-01-14 |
| NCT ID | NCT06848387 |
| Official listing | https://clinicaltrials.gov/study/NCT06848387 |